Cargando…

Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23

Psoriasis is a chronic, recurrent, immune-mediated disease involving the skin and joints. Epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation, and excess T helper type-1 (Th-1) and Th-17 cell infiltration are the main histopathological featu...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jiun-Wen, Cheng, Yu-Pin, Liu, Chih-Yi, Thong, Haw-Yueh, Lo, Yang, Wu, Chen-Yu, Jee, Shiou-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967813/
https://www.ncbi.nlm.nih.gov/pubmed/33747183
http://dx.doi.org/10.3892/etm.2021.9876
_version_ 1783665957956222976
author Guo, Jiun-Wen
Cheng, Yu-Pin
Liu, Chih-Yi
Thong, Haw-Yueh
Lo, Yang
Wu, Chen-Yu
Jee, Shiou-Hwa
author_facet Guo, Jiun-Wen
Cheng, Yu-Pin
Liu, Chih-Yi
Thong, Haw-Yueh
Lo, Yang
Wu, Chen-Yu
Jee, Shiou-Hwa
author_sort Guo, Jiun-Wen
collection PubMed
description Psoriasis is a chronic, recurrent, immune-mediated disease involving the skin and joints. Epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation, and excess T helper type-1 (Th-1) and Th-17 cell infiltration are the main histopathological features of psoriasis. Magnolol is a polyphenolic compound that exerts its biological properties through a variety of mechanisms such as the NF-κB/MAPK, Nrf2/HO-1 and PI3K/Akt pathways. Magnolol has been demonstrated to exert a number of therapeutic effects on dermatological processes, including acting as an anti-inflammation, antiproliferation and antioxidation agent. However, few studies have been published on the effect of magnolol on psoriasis. Therefore, the present study aimed to elucidate the mechanism of action of magnolol on psoriasis. BALB/c mice were treated topically with imiquimod (IMQ) to induce psoriasis-like dermatitis, and were randomly assigned to the control, vehicle control, low- and high-dose magnolol, and 0.25% desoximetasone ointment treatment groups in order to investigate skin barrier function, any changes in the levels of cytokines and for the histological assessment. High doses of magnolol were indicated to be able to improve the barrier function following IMQ-induced barrier disruption. Magnolol activated peroxisome proliferator-activated receptor-γ, and also significantly inhibited the protein expression of interleukin (IL)-23, IL-1β, IL-6, tumor necrosis factor-α and interferon-γ. However, administering a high dose of magnolol did not lead to any improvement in the clinical and pathological features of the psoriasis severity Taken together, these results demonstrated that downregulation of IL-23 may contribute to barrier function improvement in a psoriatic skin model.
format Online
Article
Text
id pubmed-7967813
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-79678132021-03-19 Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23 Guo, Jiun-Wen Cheng, Yu-Pin Liu, Chih-Yi Thong, Haw-Yueh Lo, Yang Wu, Chen-Yu Jee, Shiou-Hwa Exp Ther Med Articles Psoriasis is a chronic, recurrent, immune-mediated disease involving the skin and joints. Epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation, and excess T helper type-1 (Th-1) and Th-17 cell infiltration are the main histopathological features of psoriasis. Magnolol is a polyphenolic compound that exerts its biological properties through a variety of mechanisms such as the NF-κB/MAPK, Nrf2/HO-1 and PI3K/Akt pathways. Magnolol has been demonstrated to exert a number of therapeutic effects on dermatological processes, including acting as an anti-inflammation, antiproliferation and antioxidation agent. However, few studies have been published on the effect of magnolol on psoriasis. Therefore, the present study aimed to elucidate the mechanism of action of magnolol on psoriasis. BALB/c mice were treated topically with imiquimod (IMQ) to induce psoriasis-like dermatitis, and were randomly assigned to the control, vehicle control, low- and high-dose magnolol, and 0.25% desoximetasone ointment treatment groups in order to investigate skin barrier function, any changes in the levels of cytokines and for the histological assessment. High doses of magnolol were indicated to be able to improve the barrier function following IMQ-induced barrier disruption. Magnolol activated peroxisome proliferator-activated receptor-γ, and also significantly inhibited the protein expression of interleukin (IL)-23, IL-1β, IL-6, tumor necrosis factor-α and interferon-γ. However, administering a high dose of magnolol did not lead to any improvement in the clinical and pathological features of the psoriasis severity Taken together, these results demonstrated that downregulation of IL-23 may contribute to barrier function improvement in a psoriatic skin model. D.A. Spandidos 2021-05 2021-03-01 /pmc/articles/PMC7967813/ /pubmed/33747183 http://dx.doi.org/10.3892/etm.2021.9876 Text en Copyright: © Guo et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Guo, Jiun-Wen
Cheng, Yu-Pin
Liu, Chih-Yi
Thong, Haw-Yueh
Lo, Yang
Wu, Chen-Yu
Jee, Shiou-Hwa
Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
title Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
title_full Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
title_fullStr Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
title_full_unstemmed Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
title_short Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
title_sort magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967813/
https://www.ncbi.nlm.nih.gov/pubmed/33747183
http://dx.doi.org/10.3892/etm.2021.9876
work_keys_str_mv AT guojiunwen magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23
AT chengyupin magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23
AT liuchihyi magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23
AT thonghawyueh magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23
AT loyang magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23
AT wuchenyu magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23
AT jeeshiouhwa magnololmaycontributetobarrierfunctionimprovementonimiquimodinducedpsoriasislikedermatitisanimalmodelviathedownregulationofinterleukin23